title: Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90).
abstract: Retinitis pigmentosa (RP) is the most prevalent cause of registered visual handicap among working aged populations of developed countries. Up to 40% of autosomal dominant cases of disease are caused by mutations within the rhodopsin, RDS-peripherin and inosine 5'-monophosphate dehydrogenase type 1 (IMPDH1) genes, at least 30 mutations within which give rise to proteins that cause disease pathology by misfolding and aggregation. Given the genetic complexity of this disease, therapies that simultaneously target multiple mutations are of substantial logistic and economic significance. We show here, in a murine model of autosomal dominant RP (RP10) involving expression of an Arg224Pro mutation within the IMPDH1 gene, that treatment with the low-molecular-weight drug, 17-allylamino-17-demethoxygeldanamycin (17-AAG), an ansamycin antibiotic that binds to heat shock protein Hsp90, activating a heat shock response in mammalian cells, protects photoreceptors against degeneration induced by aggregating mutant IMPDH1 protein, systemic delivery of this low-molecular-weight drug to the retina being facilitated by RNA interference-mediated modulation of the inner-blood retina barrier. 17-AAG has an orphan drug status and is in current clinical use for the treatment of non-ocular diseases. These data show that a single low-molecular-weight drug has the potential to suppress a wide range of mutant proteins causing RP.
authors.affiliation: The Ocular Genetics Unit, Department of Genetics, Trinity College Dublin, Dublin 2, Ireland.
authors.forename: Lawrence C S
authors.initials: LC
authors.lastname: Tam
authors.forename: Anna-Sophia
authors.initials: AS
authors.lastname: Kiang
authors.forename: Matthew
authors.initials: M
authors.lastname: Campbell
authors.forename: James
authors.initials: J
authors.lastname: Keaney
authors.forename: G Jane
authors.initials: GJ
authors.lastname: Farrar
authors.forename: Marian M
authors.initials: MM
authors.lastname: Humphries
authors.forename: Paul F
authors.initials: PF
authors.lastname: Kenna
authors.forename: Pete
authors.initials: P
authors.lastname: Humphries
mesh_terms: D000818:Animals; D016227:Benzoquinones / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D005799:Genes, Dominant; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D007168:IMP Dehydrogenase / Q000235:genetics / Q000378:metabolism; D047029:Lactams, Macrocyclic / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D034622:RNA Interference; D012160:Retina / Q000187:drug effects; D012174:Retinitis Pigmentosa / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D012243:Rhodopsin / Q000235:genetics / Q000378:metabolism
chemical_list: D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C112765:tanespimycin; D012243:Rhodopsin; D007168:IMP Dehydrogenase
references.citation: J Biol Chem. 1994 Dec 9;269(49):30761-4
references.pmid: 7983002
references.citation: Cancer Chemother Pharmacol. 2001 Apr;47(4):291-302
references.pmid: 11345645
references.citation: Cell Mol Life Sci. 2005 Mar;62(6):670-84
references.pmid: 15770419
references.citation: J Gene Med. 2008 Aug;10(8):930-47
references.pmid: 18509865
references.citation: Nat Genet. 1997 Feb;15(2):216-9
references.pmid: 9020854
references.citation: Cancer Chemother Pharmacol. 2005 Aug;56(2):115-25
references.pmid: 15791458
references.citation: J Biol Chem. 2008 Sep 19;283(38):26188-97
references.pmid: 18632670
references.citation: N Engl J Med. 2008 May 22;358(21):2231-9
references.pmid: 18441371
references.citation: Nature. 1995 Jul 6;376(6535):37-43
references.pmid: 7596430
references.citation: Annu Rev Genet. 1993;27:437-96
references.pmid: 8122909
references.citation: Hum Mol Genet. 2004 Jul 1;13(13):1389-405
references.pmid: 15115766
references.citation: Am J Hum Genet. 2007 Jul;81(1):127-35
references.pmid: 17564969
references.citation: Nat Med. 2006 Jan;12(1):128-32
references.pmid: 16327803
references.citation: Exp Biol Med (Maywood). 2003 Feb;228(2):111-33
references.pmid: 12563018
references.citation: Nat Med. 2005 Oct;11(10):1088-95
references.pmid: 16155577
references.citation: Hum Mol Genet. 2009 Mar 1;18(5):898-910
references.pmid: 19066230
references.citation: Lancet. 2009 Nov 7;374(9701):1597-605
references.pmid: 19854499
references.citation: Nat Genet. 1999 Dec;23(4):425-8
references.pmid: 10581028
references.citation: Neurodegener Dis. 2007;4(2-3):254-60
references.pmid: 17596719
references.citation: Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5961-6
references.pmid: 20231467
references.citation: Hum Gene Ther. 2009 Sep;20(9):999-1004
references.pmid: 19583479
references.citation: BMC Neurosci. 2008 Dec 03;9 Suppl 2:S5
references.pmid: 19090993
references.citation: Leukemia. 2010 Apr;24(4):699-705
references.pmid: 20111068
references.citation: Curr Opin Drug Discov Devel. 2009 Sep;12(5):666-81
references.pmid: 19736625
references.citation: Cancer Lett. 2010 Apr 1;290(1):24-35
references.pmid: 19850405
references.citation: Prog Retin Eye Res. 2008 Jul;27(4):434-49
references.pmid: 18490186
references.citation: J Clin Invest. 2007 Mar;117(3):648-58
references.pmid: 17304350
references.citation: Nature. 1991 Dec 12;354(6353):478-80
references.pmid: 1749427
references.citation: J Biol Chem. 2002 Sep 13;277(37):34150-60
references.pmid: 12091393
references.citation: Hum Mol Genet. 2001 Jun 1;10(12):1307-15
references.pmid: 11406612
references.citation: Hum Mol Genet. 2008 Jul 15;17(14):2084-100
references.pmid: 18385099
references.citation: J Cell Sci. 2002 Jul 15;115(Pt 14):2907-18
references.pmid: 12082151
references.citation: BMC Bioinformatics. 2007 Feb 27;8:65
references.pmid: 17324296
references.citation: Clin Cancer Res. 2005 May 1;11(9):3385-91
references.pmid: 15867239
references.citation: Neuron. 1992 Nov;9(5):815-30
references.pmid: 1418997
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1078-87
references.pmid: 15718306
references.citation: Hum Mol Genet. 2000 Nov 22;9(19):2811-20
references.pmid: 11092757
references.citation: Cell. 1998 Aug 21;94(4):471-80
references.pmid: 9727490
references.citation: Clin Lymphoma Myeloma. 2006 May;6(6):500-1
references.pmid: 16796784
references.citation: Mol Biol Cell. 2008 Mar;19(3):899-911
references.pmid: 18094050
references.citation: Nature. 2002 Aug 15;418(6899):729-30
references.pmid: 12181546
references.citation: Bioinformatics. 2009 Oct 1;25(19):2537-43
references.pmid: 19654118
references.citation: Hum Mol Genet. 2002 Mar 1;11(5):547-57
references.pmid: 11875049
references.citation: J Biol Chem. 2008 Dec 26;283(52):36354-60
references.pmid: 18974094
references.citation: Curr Cancer Drug Targets. 2003 Oct;3(5):377-83
references.pmid: 14529389
references.citation: Lancet. 2006 Nov 18;368(9549):1795-809
references.pmid: 17113430
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):2261-70
references.pmid: 17404111
references.citation: Hum Mol Genet. 2008 Oct 1;17(19):3043-54
references.pmid: 18635576
references.citation: Adv Cancer Res. 2006;95:323-48
references.pmid: 16860662
references.citation: Neuropathol Appl Neurobiol. 1993 Feb;19(1):10-21
references.pmid: 8386339
references.citation: Hum Mol Genet. 2004 Mar 15;13(6):641-50
references.pmid: 14981049
references.citation: Nature. 1990 Jan 25;343(6256):364-6
references.pmid: 2137202
references.citation: Biochemistry. 2010 Feb 9;49(5):905-11
references.pmid: 20055437
references.citation: J Neurochem. 2002 Apr;81(2):355-64
references.pmid: 12064483
references.citation: Nat Rev Mol Cell Biol. 2004 Oct;5(10):781-91
references.pmid: 15459659
references.citation: Genet Med. 2005 Jan;7(1):3-12
references.pmid: 15654222
references.citation: Am J Med Genet A. 2003 Jul 30;120A(3):320-5
references.pmid: 12838549
references.citation: Brain Res Bull. 2010 Jan 15;81(1):12-24
references.pmid: 19808079
references.citation: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17817-22
references.pmid: 19822744
references.citation: Trends Mol Med. 2005 Apr;11(4):177-85
references.pmid: 15823756
references.citation: Hum Mol Genet. 2002 Mar 1;11(5):559-68
references.pmid: 11875050
references.citation: Nat Med. 2004 Jul;10 Suppl:S10-7
references.pmid: 15272267
references.citation: Mol Ther. 2005 Sep;12(3):555-61
references.pmid: 15967729
references.citation: Nat Med. 2002 Nov;8(11):1185-6
references.pmid: 12411925
references.citation: Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2878-87
references.pmid: 18408180